Israel only reviews a device with no clearance elsewhere

This blog has already covered how Korea routes a device to one of three review bodies by class, and how a Canadian device licence leans on an MDSAP audit somebody else already ran. Israel's system goes a step further than either. AMAR — the Medical Device Division of Israel's Ministry of Health, the unit that administers the Medical Equipment Law, 5772-2012 — doesn't just accept a foreign credential as supporting evidence. Which of its three registration routes a device gets, and how much of an independent review it receives, is decided almost entirely by whether that foreign credential already exists.

Three routes, sorted by an approval that already happened

The Medical Equipment Law doesn't define a single review process for every device seeking entry to the Israeli market. AMAR's own regulations split submissions across a Declaration Route, two tiers of Fast-Track review, and a Normal Route — and the sorting question isn't the device's own risk in the abstract. It's whether the device already carries a marketing authorization in a country AMAR recognizes as a reference market: the United States, the European Union, Canada, or Australia, with Japan sometimes accepted as well.

Declaration and Fast-Track both borrow a decision already made

Under the Declaration Route, a manufacturer can register through self-declaration alone, provided the device already holds approval and has actually been marketed in a recognized reference country. Fast-Track Route 1 covers moderate-risk devices — FDA Class II, EU Class IIa — that have carried reference-country approval and market presence for at least four months, reviewed on a roughly 45-business-day clock. Fast-Track Route 2 raises the bar for higher-risk devices, such as EU MDR Class IIb: approval in two separate reference countries, at least six months of market history in one of them, and a roughly 60-business-day review. Neither Fast-Track tier asks AMAR to independently re-examine the clinical case a manufacturer already argued somewhere else.

The Normal Route is the exception doing the real work

Devices without qualifying reference-country approval land on the Normal Route instead — a 120-calendar-day target that guidance and practitioners alike describe running closer to four to six months in practice. It's on this route, and largely only this one, that AMAR asks for the file a from-scratch review actually needs: a risk analysis, a clinical evaluation, a summary of clinical trial data. A team that assumes every Israeli registration passed through that kind of scrutiny has the system backward. For most devices entering the market, the reference-country approval is the entry point; AMAR's own clinical review is the fallback for the minority that arrive without one.

The Israeli file's standing depends on a foreign one

A quality management system credential rides alongside every route regardless — AMAR expects an ISO 13485 certificate or comparable evidence whichever path a device takes. But the routes that skip AMAR's own clinical review haven't skipped dependency on the file behind them: a registration built on a reference country's approval is only as durable as that approval remains. A registration record that stores Israel's status as a flat “registered” line, with no reference to which route it entered on or which foreign approval it's still leaning on, has recorded a conclusion without the fact the conclusion actually rests on.

Where this meets the file

A cross-border tracker's Israel row needs the route recorded as its own field — Declaration, Fast-Track 1, Fast-Track 2, or Normal — alongside whichever reference country's approval that route depended on, not folded into a single pass/fail status. A registration tracker built around that structure, alongside the launch catalog's other cross-border templates, is previewed there now. If your program has tracked AMAR's routes differently, the shelf takes that correction directly.